Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)Defense World · 2 days ago
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersGlobeNewsWire · Oct 9, 2026
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesGlobeNewsWire · Oct 8, 2026
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · Oct 8, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 1, 2026
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a TurnaroundZacks Investment Research · Sep 24, 2026X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.18 | -$0.13 | Beat |
| May 6, 2026 | -$0.20 | -$0.16 | Beat |
| Mar 17, 2026 | -$0.36 | -$0.22 | Beat |
| Nov 5, 2025 | -$0.79 | -$0.69 | Beat |
| Aug 8, 2025 | -$4.53 | -$3.47 | Beat |
| May 1, 2025 | -$4.13 | $0.04 | Beat |